FURUNO-ELECTRIC
20.8.2024 06:01:33 CEST | Business Wire | Press release
Furuno Electric is delighted to announce that the company will participate in Jammertest 2024 in Andøya, Norway from 9 to 13 September.
The participants will test GNSS receivers in an environment where they will actually be exposed to jamming and spoofing* signals and obtain data on their tolerance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240819796325/en/
Jammertest 2024 (Graphic: Business Wire)
About Jammertest
This Jammertest is the world's largest test event where resistance to jamming and spoofing can be tested in a real environment. It is organized by the Norwegian Public Roads Administration, Norwegian Communications Authority, Norwegian Defence Research Establishment, Norwegian Metrology Service, Norwegian Space Agency and Testnor.
Jamming has actually been detected in the Black Sea, Northern Europe, and the Middle East, and there is a growing need for enhanced resiliency in critical infrastructure such as traffic control and mobile communications. Furuno has been testing its receivers by creating signals that simulate jamming and spoofing in a lab environment, but to verify and improve our anti-jamming capabilities, it is ideal to perform a variety of evaluations in a real environment. To allow participating companies and institutions to test their GNSS receiver-equipped products in a real-world environment, the organizer will conduct various types of jamming and spoofing attacks during the event.
The resistance test Furuno will carry out
In this Jammertest, Furuno will test the jamming and spoofing resistance of GT-100 which is Furuno’s timing multi-GNSS receiver module that supports dual-frequency band reception in the L1 and L5 bands. GNSS receivers for time synchronization are used in critical infrastructures that require robustness, such as 5G mobile base stations, TV broadcasting, financial institutions, and power grids. The latest product, GT-100, can automatically mitigate the effects of jamming and spoofing signals while providing users with real-time notification of the jamming signal frequency and signal strength. Also, if it completely loses reception of the L1 band signal, it can still maintain reception of the L5 band signal and continuously output stable time.
By participating in the Jammertest 2024, Furuno will evaluate and analyze the level of resistance of GT-100 to jamming and spoofing in real-world environments and use the results to further improve its robustness.
About Jammertest 2024
Official name of the event: Jammertest 2024
Event dates: September 9 - 13, 2024
Location: Andøya, Norway
Official website: https://jammertest.no/jammertest/
Products Tested
Timing Multi-GNSS Receiver Module GT-100
https://www.furuno.com/en/products/gnss-module/GT-100
Multi-GNSS Timing Antennas AU-500
https://www.furuno.com/en/products/gnss-antenna/AU-500
* Jamming and Spoofing: Jamming means radio waves that interfere with GNSS signals. Spoofing means that malicious actors intentionally mimic and broadcast GNSS-like signals with the intent to trick nearby GNSS receivers into calculating incorrect position and/or time.
Related Links
Announced on May 16, 2023: Furuno Announces High-Performance Multi-GNSS Timing Antennas
https://www.furuno.co.jp/en/news/general/general_category.html?itemid=1320&dispmid=961
Announced on September 14, 2022: Furuno Announces Most Advanced Global Timing Solutions Supporting L1 and L5 GNSS Signals
https://www.furuno.co.jp/en/news/general/general_category.html?itemid=1216&dispmid=961
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819796325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom